Intensive Care Unit requirements in patients treated with immune checkpoint inhibitors
AffiliationDepartments of Acute Medicine, Medical Oncology and Critical Care, The Christie, Wilmslow Road, Manchester, UK.
MetadataShow full item record
AbstractObjective: To determine the proportion of emergency patients treated with immune checkpoint inhibitors (ICIs) that require critical care admission and their requirements. Design: Prospective case series. Methods: Analysis of acutely unwell patients treated with ICIs attending a tertiary UK cancer hospital between May 2018 and May 2022. The primary outcome measure was the percentage of patients treated with ICI therapy requiring ICU admission. The secondary outcome measure was whether this need was driven by an immune-mediated toxicity. Results: Eighteen (1.2%) patients of the 1561 acutely admitted patients treated with ICI therapy required an admission to ICU. Ten (55.5%) patients were admitted due to an immune-mediated toxicity; 4 due to pneumonitis and 4 due to myasthenia gravis. Seven of 10 survived their ICU admission with 6 surviving at least 6 month post ICU discharge. Conclusions: Only a small minority of emergency admissions in patients treated with ICIs require admission to ICU. This series adds further evidence that patients with organ failure due to immune-mediated toxicity may achieve good outcomes from ICU admission.
CitationCooksley T, Weaver JMJ, Haji-Michael P. Intensive Care Unit requirements in patients treated with immune checkpoint inhibitors. QJM : monthly journal of the Association of Physicians. 2022 Nov 15. PubMed PMID: 36377790. Epub 2022/11/16. eng.
- Emergency presentations in patients treated with immune checkpoint inhibitors.
- Authors: Cooksley T, Gupta A, Al-Sayed T, Lorigan P
- Issue date: 2020 May
- Outcome of children requiring admission to an intensive care unit after bone marrow transplantation.
- Authors: Jacobe SJ, Hassan A, Veys P, Mok Q
- Issue date: 2003 May
- Association of an Emergency Department-embedded Critical Care Unit with Hospital Outcomes and Intensive Care Unit Use.
- Authors: Anesi GL, Chelluri J, Qasim ZA, Chowdhury M, Kohn R, Weissman GE, Bayes B, Delgado MK, Abella BS, Halpern SD, Greenwood JC
- Issue date: 2020 Dec
- Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit.
- Authors: Deharo F, Carvelli J, Cautela J, Garcia M, Sarles C, Maues de Paula A, Bourenne J, Gainnier M, Bichon A
- Issue date: 2022 Sep 23
- Critically ill patients with severe immune checkpoint inhibitor related neurotoxicity: A multi-center case series.
- Authors: Rajendram P, Torbic H, Duggal A, Campbell J, Hovden M, Dhawan V, Pastores SM, Gutierrez C
- Issue date: 2021 Oct